-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

1657 The Integrated Immunological Signature of Refractory Cytopenia of Childhood (RCC)

Myelodysplastic Syndromes – Basic and Translational Studies
Program: Oral and Poster Abstracts
Session: 636. Myelodysplastic Syndromes – Basic and Translational Studies: Poster I
Saturday, December 5, 2015, 5:30 PM-7:30 PM
Hall A, Level 2 (Orange County Convention Center)

Demi de Winter1*, Marry M van den Heuvel-Eibrink, MD, PhD2,3*, Vincent H.J. van der Velden, PhD4*, Anton W. Langerak5*, Jacques J.M. Dongen1*, Michael Dworzak, MD6*, Barbara De Moerloose, MD, PhD7*, Jan Starý, MD8*, Charlotte M Niemeyer, MD, PhD9, Franco Locatelli, MD10, Henrik Hasle, MD11, Markus Schmugge, MD12, C. Michel Zwaan, MD, PhD13 and Rob Pieters, MD, PhD14,15

1Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
2Department of Pediatric Oncology, Princess Maxima Center for Paediatric Oncology, Utrecht, Netherlands
3Department of Paediatric Oncology/Hematology, Erasmus MC-Sophia’s Children’s Hospital, Rotterdam, Netherlands
4Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, Netherlands
5Department of Immunology, Erasmus MC Rotterdam, Rotterdam, Netherlands
6Department of Pediatrics, Medical University of Vienna, St. Anna Children's Hospital and Children’s Cancer Research Institute, Vienna, Austria
7Department of Pediatrics, Ghent University, Ghent, Belgium
8Department of Pediatric Hematology and Oncology, Charles University and Univ Hospital Motol, Prague, Czech Republic
9Universitaets-Kinderklinik, Freiburg, Germany
10Department of Pediatric Hematology and Oncology, IRCCS Ospedale Pediatrico Bambino Gesù, Rome, Italy
11Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark
12Haematology, University Children's Hospital Zurich, Zurich, Switzerland
13Pediatric Oncology/Hematology, Erasmus MC-Sophia Children's hospital, Rotterdam, Netherlands
14Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
15Department of Pediatric Oncology/Hematology, Erasmus MC - Sophia Children's Hospital, Rotterdam, Netherlands

Refractory cytopenia of childhood (RCC) is the most common subtype of childhood myelodysplastic syndrome (MDS). Clinical and laboratory evidence suggest a T-cell mediated pathophysiology in a subset of adult patients with low-grade MDS. Recently, it was shown that in RCC, indicators of an immune-mediated pathophysiology are frequently present. These indicators included the presence of minor paroxysmal nocturnal haemoglobinuria (PNH) clones and T cell receptor (TCR) β-chain variable (Vβ) domain (TCRVβ) skewing. In addition, aberrant immunophenotypes are frequently identified in RCC patients.   

It is however still unknown to what extend these immune phenomena concomitantly occur in low-grade MDS. Therefore, in the current study we integrated the presence of minor PNH clones, TCRVβ skewing and immunophenotypic aberrancies in a large international cohort of 72 RCC patients.

Small PNH clones were present in 31 cases (43%), TCRVβ skewing in 30 cases (42%), and immunophenotypic aberrancies in 43 cases (60%). In only 9 patients (13%) all these three were present. Two parameters were present in 25 patients (35%), and 27 patients (38%) displayed only one parameter. In 11 patients (15%) none of the three characteristics was present.

Figure 1: Venn diagram depicting the overlap between flow cytometric aberrant immunophenotype, PNH clones and TCRVβ skewing in RCC.

Tekstvak: Figure 1: Venn diagram depicting the overlap between flow cytometric aberrant immunophenotype, PNH clones and TCRVβ skewing in RCC.

The most prominent parameter was the presence of an aberrant immunophenotype, which was associated with TCRVβ skewing (n=18) or the presence of PNH clones (n= 20) in a subset of the patients. Hypocellular RCC patients with a small PNH clone (>0.1%) were more likely to respond to IST than PNH negative patients (88% versus 40% of patients responded at six months, respectively, P=0.038). From the current study we could not predict the strongest predictable value of combined parameters, with respect to response on immunosuppressive therapy (IST) in RCC patients, as only 23 patients were treated with IST.

We conclude that RCC patients frequently show immunological aberrancies, but that the presence of and combination with PNH and TCRVB skewing is rather heterogeneous. However, our study underscores the fact that in RCC, which might be challenging to diagnose based on morphology only due to hypoplasia, bone marrow immunophenotyping by flow cytometry, combined with either TCRVβ skewing or the presence of PNH clones, may be of important diagnostic value. Future studies in extended RCC series are required to build a prediction model for response to immunosuppressive therapy.

Disclosures: Langerak: Roche: Other: Lab services in the field of MRD diagnostics provided by Dept of Immunology, Erasmus MC (Rotterdam) ; InVivoScribe: Patents & Royalties: Licensing of IP and Patent on BIOMED-2-based methods for PCR-based Clonality Diagnostics. ; DAKO: Patents & Royalties: Licensing of IP and Patent on Split-Signal FISH. Royalties for Dept. of Immunology, Erasmus MC, Rotterdam, NL .

*signifies non-member of ASH